Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adastra Pharmaceuticals, Inc.

https://www.adastrarx.com/

Latest From Adastra Pharmaceuticals, Inc.

Flow Forward Medical Inc.

The most desirable form of vascular access for most hemodialysis patients is an arteriovenous fistula (AVF). Flow Forward believes it can expand the AVF prevalence rate to 90% with its Arteriovenous Fistula Eligibility (AFE) System, a temporary external blood pump that rapidly dilates peripheral veins prior to AVF surgery.

Medical Device

Jinghua Aims To Transform Through Kadmon Biologics Alliance

China-listed Jinghua Pharmaceutical has tapped into developing biologic drug through investment and licensing agreement with US-based Kadmon, shifting from a traditional Chinese medicine maker to mAbs developer. The company has seen increasing competition and revenue drops in Chinese traditional medicine industry.

BioPharmaceutical China

First Minimally Invasive Vascular Access Technology Has Potential to Revolutionize Growing Hemodialysis Market

With a projected worldwide market of over three million hemodialysis patients by 2020, TVA Medical Inc. sees a potential $1 billion+ annual market opportunity with everlinQ, a minimally invasive, catheter-based system that allows physicians to use an endovascular approach to create an arteriovenous fistula (AVF) for vascular access in chronic kidney patients who require ongoing hemodialysis.

Medical Device Innovation

Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations

DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • Tragara Pharmaceuticals, Inc.
UsernamePublicRestriction

Register